Medigene AG, a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announced that it has sold 50 per cent of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. € 6.1 million).
Medigene held 64,815 ordinary shares in Immunocore which were valued at 2.8 million GBP (approx. € 3.6 million) in 2014.
Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalised T-cell-based immunotherapies.